Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single- and Multiple-Ascending Dose Study of LY3971297 in Healthy Participants, Participants With Obesity and Hypertension, and Participants With Decreased eGFR
jRCT2051250017Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 1, randomised, double-blind trial of LY-3971297 in obesity, hypertension (HTN) and chronic kidney disease (CKD) (13 arms), sponsored by Eli Lilly and Company. Started Jun 2025; status: active, not recruiting.
02
Drugs
LY-3971297
03
Conditions
obesityhypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2051250017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250017.